#None #Norgine #WHIM syndrome #XOLREMDI

Norgine's Milestone Approval for XOLREMDI®

In a significant breakthrough for patients suffering from the rare WHIM syndrome, Norgine, a prominent European specialty pharmaceutical company, has announced the European Commission's grant of marketing authorization for XOLREMDI® (Mavorixafor). WHIM syndrome, an acronym for Warts, Hypogammaglobulinemia, Infections, and Myelokathexis, is a primary immunodeficiency disorder that leads to severe recurrent infections due to the disruption of white blood cell mobilization from bone marrow to the bloodstream.

The Approval Process

This landmark decision follows a positive recommendation from the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA). The authorization was issued under exceptional circumstances, which underscores the urgent need for treatment options available to those affected by such rare conditions. XOLREMDI® is indicated for patients aged 12 and older, effectively increasing the number of circulating mature neutrophils and lymphocytes to enhance immune response.

Janneke van der Kamp, CEO of Norgine, expressed her enthusiasm about the approval, stating, "The authorization of XOLREMDI® in the European Union marks a significant milestone for individuals living with WHIM syndrome, a condition that previously had no authorized treatment options. We are committed to bringing much-needed therapies to patients across Europe, Australia, and New Zealand and look forward to working closely with health authorities and the rare disease community to make Mavorixafor available as soon as possible."

Understanding WHIM Syndrome

WHIM syndrome is associated with a defect in the CXCR4 receptor, which plays a critical role in the normal release of white blood cells from the bone marrow. Patients typically present with symptoms including verrucae (warts), hypogammaglobulinemia (low levels of immunoglobulins), recurrent infections, and myelokathexis (the retention of white blood cells in the bone marrow). As a result, individuals are at a heightened risk for severe infections, leading to considerable impacts on their quality of life.

Clinical Evidence and Studies

The EU marketing authorization is supported by outcomes from the pivotal Phase 3 WHIM study, a global randomized, double-blind, placebo-controlled trial that evaluated the safety and efficacy of Mavorixafor in 31 diagnosed patients aged 12 and older. The results demonstrated a promising safety profile and an increase in the levels of key immune cells, suggesting a potential for reducing infection rates among patients.

Johan Prevot, Executive Director of IPOPI, the International Patient Organization for Primary Immunodeficiencies, noted, "This approval marks a significant moment for the WHIM syndrome community in Europe. For patients and families dealing with recurrent severe infections and the burdens of this rare primary immunodeficiency, the availability of an authorized treatment is a monumental step forward.” He emphasized the organization's ongoing commitment to advocating for patient voices across Europe to ensure equitable access to innovative treatments.

Future Outlook

Norgine has entered into a license and supply agreement with X4 Pharmaceuticals, as of January 2025, to market Mavorixafor in Europe, Australia, and New Zealand post-approval. Under this agreement, Norgine will be responsible for all market access and commercialization activities while X4 will handle manufacturing and supply of the medication.

Conclusion

Norgine's approval for XOLREMDI® represents hope for individuals affected by WHIM syndrome, offering an avenue for improved health outcomes. As the company gears up for market introduction, the focus now lies on collaboration with healthcare professionals, regulatory authorities, and the rare disease community to facilitate patient access to this groundbreaking therapy. Through innovative approaches and a strong commitment to addressing unmet medical needs, Norgine is poised to make a significant impact in the lives of patients needing effective treatments for rare diseases.